Barely Significant
← all excerpts

CBX1 is involved in hepatocellular carcinoma progression and resistance to sorafenib and lenvatinib via IGF-1R/AKT/SNAIL signaling pathway.

Hepatol Int · 2024 · PMC11461582 · PMID 38769286

Europe PMCDOI
1
hedged sentence
0.0500
closest p · 1.0× alpha
0.0500
boldest claim

The sentences

a positive trendp < 0.05actually significant
Disease-free survival analysis also showed a negative impact of high CBX1 expression in ACC, ESCA, KICH, and LIHC, whereas a positive trend was noted in KIRC, THCA, and UCS (all p < 0.05; Fig. 2 A/B).

also in 2,751 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.